Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSCW) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to 0.38.

  • Ensysce Biosciences' Equity Ratio fell 4858.39% to 0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.38, marking a year-over-year decrease of 4858.39%. This contributed to the annual value of 0.66 for FY2024, which is 37549.84% up from last year.
  • Ensysce Biosciences' Equity Ratio amounted to 0.38 in Q3 2025, which was down 4858.39% from 0.61 recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Equity Ratio registered a high of 0.74 during Q3 2024, and its lowest value of 0.77 during Q3 2022.
  • Its 5-year average for Equity Ratio is 0.16, with a median of 0.25 in 2022.
  • Its Equity Ratio has fluctuated over the past 5 years, first crashed by 185389.27% in 2022, then soared by 37549.84% in 2024.
  • Ensysce Biosciences' Equity Ratio (Quarter) stood at 0.5 in 2021, then tumbled by 37.8% to 0.68 in 2022, then soared by 64.88% to 0.24 in 2023, then skyrocketed by 375.5% to 0.66 in 2024, then tumbled by 42.87% to 0.38 in 2025.
  • Its Equity Ratio stands at 0.38 for Q3 2025, versus 0.61 for Q2 2025 and 0.66 for Q1 2025.